Displaying results 1 - 3 of 3
Clear search
F-star wins Best Partnership Alliance Award at the 14th Annual Scrip Awards
F-star, a clinical-stage biopharmaceutical company pioneering the development of novel bispecific antibodies that target the immune system to fight cancer, this week won “Best Partnership Alliance” at the Scrip Awards ceremony.
F-star expands its relationship with Merck through a new strategic collaboration
F-star, a biopharmaceutical company developing novel bispecific antibodies, announces today a new partnership with Merck, a leading science and technology company, for the development and commercialisation of five bispecific immuno-oncology antibodies (mAb2 ™).
F- star: Phase 1 trial for FS102 for treatment of HER2 positive breast and gastric cancer
F-star, a biopharmaceutical company focused on oncology and immunooncology, today announced the initiation of a phase 1 clinical study of FS102, its lead compound for treatment of HER2-positive breast and gastric cancer.